Aims: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors treat type 2 diabetes through incretin-signaling pathways. This study compared the efficacy and safety of the glucagon-like peptide-1 receptor agonist exenatide once-weekly (Miglyol) suspension for autoinjection (QWS-AI) with the dipeptidyl peptidase-4 inhibitor sitagliptin or placebo.
GLP-1RA exenatide was initially developed as a twice-daily (BID) injection. 3 A once-weekly (QW) formulation was later developed, 4 containing the active ingredient of exenatide BID encapsulated into biodegradable poly(D,L-lactide-coglycolide) microspheres. 5 Exenatide QW is administered using a single-dose tray, with some assembly required, 6 or as a pre-assembled single-dose dual-chamber pen. 7 For both devices, patients need to mix exenatide-containing microspheres and aqueous diluent before injection. 4, 7 Exenatide delivery has been further simplified by the development of a QW suspension for autoinjection (QWS-AI), in which the microspheres are suspended in a mixture of nonaqueous triglycerides (Miglyol 812). The autoinjector delivers a single 2.0-mg exenatide dose (as do all QW delivery systems) in a premeasured volume (0.85 mL), eliminating the need for reconstitution and improving mixing speed. Pharmacokinetic data demonstrated that exenatide 2.0 mg QWS-AI achieved steady-state exenatide concentrations within the range observed with exenatide 2.0 mg QW; 8 thus, the dosage was considered appropriate for future investigation.
Previous studies compared the efficacy and safety of GLP-1RAs with DPP-4is. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] The DURATION-2 and DURATION-4 studies demonstrated that exenatide QW achieved better glycaemic control than sitagliptin, both as monotherapy and in combination with metformin. 9, 10 This study compared the efficacy and safety of the exenatide QWS-AI formulation vs the maximum approved dose of sitagliptin and vs placebo among patients receiving suboptimal glycaemic control with metformin monotherapy.
| MATERIALS AND METHODS
This phase 3, randomized, open-label, multicentre, active-and placebo-controlled study (DURATION-NEO-2; NCT01652729), conducted at 81 centres in the USA between February 2013 and April 2014, comprised a screening period (screening visit followed by second visit within 14 days) and a 28-week treatment period. Study drug was initiated at randomization (baseline), 1 week after the second screening visit. Visits were conducted at 2-week intervals to week 4 and at 4-week intervals thereafter.
Eligible patients were aged ≥18 years with T2D on a stable regimen of metformin ≥1500 mg/d for ≥2 months before screening.
Additional inclusion criteria were glycated hemoglobin (HbA1c) of 7.1% to 11.0% at screening, fasting plasma glucose (FPG) <280 mg/ dL at screening and at visit 2, body mass index ≤45 kg/m 2 and stable body weight (≤3% variation for ≥3 months before screening). Exclusion criteria included any clinically significant medical condition that could affect study participation; an estimated glomerular filtration rate <30 mL/min/1.73 m 2 ; exposure to exenatide or any GLP-1RA; use of any DPP-4i, sulfonylurea or thiazolidinedione, or weight-loss medications within 3 months before screening; or ≥2 episodes of severe hypoglycaemia within 6 months of screening.
Patients provided written informed consent before enrollment.
The study protocol was approved by institutional review boards at each study site and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines.
| Randomization and blinding
Randomization was achieved centrally through an interactive web system and stratified by screening HbA1c <9.0% or ≥9.0%. Patients were randomized in a 3:2:1 ratio to exenatide 2.0 mg QWS-AI, sitagliptin 100 mg or placebo, thereby maximizing the amount of safety data for exenatide QWS-AI while minimizing the number of patients receiving placebo. Patients, investigators, study-site staff and the sponsor were blinded to the identity of sitagliptin or placebo, which were administered in capsules of identical appearance. Exenatide QWS-AI administration was not blinded, and no placebo injection was provided. Personnel involved with data review and analysis were blinded to key efficacy data throughout the 28-week assessment period.
| Treatments and procedures
Sitagliptin and placebo were administered orally once daily in the morning, and exenatide QWS-AI was administered QW by subcutaneous injection in the abdomen, thigh or upper arm via prefilled, single-dose autoinjector with an integrated needle on the same day of the week at any time of day. Before the first exenatide QWS-AI dose, a medically qualified staff member trained patients or caregivers concerning autoinjection methodology. Proportion of medication use was determined by comparison of study drug dispensed vs drug returned.
Stable doses of metformin (≥1500 mg/d) and antihypertensive and lipid-lowering agents (if applicable) were continued throughout the study. In the event of loss of glucose control (FPG > 270 mg/dL at 2 consecutive visits from weeks 4-16 or >240 mg/dL at 2 consecutive visits from weeks [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , rescue therapy with glucose-lowering treatment was initiated at the investigator's discretion.
Patients were instructed to record 6-point self-monitored blood glucose (SMBG) profiles (3 measurements 15 minutes before each of 3 main meals and 3 measurements 1.5-2 hours after each meal) on any 3 days before baseline and during weeks 16 and 28.
A subset of patients in each treatment group participated in a standardized meal test at baseline and week 16. For the meal test, patients were provided a standardized c. 660 kcal breakfast (60% carbohydrates, 15% protein, 25% fat) and this was consumed within 15 minutes.
| Efficacy measures

| Glycaemic control
The primary efficacy endpoint was change from baseline in HbA1c at 
| Cardiovascular risk markers
Change from baseline to week 28 in body weight was a secondary endpoint. Tertiary endpoints related to cardiovascular risk included changes from baseline in systolic and diastolic blood pressure, fasting lipid concentrations, B-type natriuretic peptide, urinary albumin-tocreatinine ratio, high-sensitivity C-reactive protein, heart rate and waist circumference, as well as the proportion of patients achieving a reduction in both HbA1c and body weight at week 28. Blood pressure and heart rate were assessed twice in the sitting position after the patient had rested for 5 minutes. Averages of the 2 readings were recorded.
| Patient-reported outcomes
Patient-reported endpoints (Diabetes Medication Satisfaction Tool, Impact of Weight on Quality of Life-Lite) are described and reported in File S1.
| Exenatide pharmacokinetics
Exenatide pharmacokinetics were evaluated in exenatide QWS-AItreated patients who had ≥ 1 exenatide concentration above the lower limit of quantification at week 16 or 28. Methods for exenatide pharmacokinetics analysis are provided in File S1.
| Safety and tolerability
The primary safety endpoint was incidence of adverse events (AEs).
Methods for AE analysis are provided in File S1. Anti-exenatide antibodies detected at 1/625 dilution (high dilution) were termed "highpositive"; antibodies detected at lower dilutions were termed "lowpositive."
Any reported or suspected cardiovascular events, pancreatitis, malignancies or deaths were adjudicated using prespecified criteria by a clinical events classification (CEC) committee blinded to study treatment.
Hypoglycaemia AEs were categorized as major, minor or symptoms of hypoglycaemia. Major hypoglycaemia was defined as an event that resulted in loss of consciousness, seizure or coma that resolved after administration of glucagon or glucose, or any event that required third-party assistance to resolve because of severe impairment in consciousness or behavior and was associated with a glucose concentration of <54 mg/dL. Minor hypoglycaemia was defined as a non-major hypoglycaemia event with symptoms of hypoglycaemia and a glucose concentration of <54 mg/dL. If a hypoglycaemia event did not meet symptomatic or blood glucose criteria for a major or minor event, it was classified as symptoms of hypoglycaemia (this could include events for which no blood glucose measure was available). 
| Statistical analysis
| Sample size
The protocol specified randomization of a total of 360 patients (exenatide QWS-AI, n = 180; sitagliptin, n = 120; placebo, n = 60), with an expected 15% withdrawal rate. A subset of c. 100 patients was proposed to participate in the standardized meal test assessment (exenatide QWS-AI, n = 50; sitagliptin, n = 33; placebo, n = 16). Further details of sample size calculation are provided online in File S1.
| RESULTS
| Patients
The study was completed by 311 patients (85% of those randomized) ( Figure 1 ). More placebo-treated patients (23%) discontinued than did exenatide QWS-AI-(15%) or sitagliptin-treated patients (11%). Compliance, determined by study drug received vs that planned, was between 97% and 98% among all groups. Twenty-nine patients received rescue therapy (File S1).
Demographic and baseline characteristics were similar across treatment groups, except for a larger proportion of men and a smaller proportion of Hispanic patients in the placebo group (Table 1) .
| Efficacy
| Glycaemic control
Exenatide QWS-AI led to significantly greater HbA1c reduction from baseline to week 28 vs sitagliptin (least-squares mean [LSM] difference, −0.38%; 95% confidence interval [CI], −0.70% to −0.06%; P = .021) or placebo (−0.72%; 95% CI, −1.15% to −0.30%; P = .001) ( Table 2 ). Greater HbA1c reductions with exenatide QWS-AI vs sitagliptin were observed from week 16 onward (Figure 2A ). At week 28, a higher proportion of exenatide QWS-AI-treated patients (43.1%) achieved HbA1c < 7.0% than did sitagliptin-(32.0%) or placebo-treated patients (24.6%) ( Figure 2B ).
Exenatide QWS-AI resulted in numerically greater FPG reductions than sitagliptin and greater FPG reductions than placebo (P < .001) ( Table 2 ). The difference in FPG reduction for exenatide QWS-AI vs sitagliptin was not statistically significant; thus, the hierar- LSM between-group differences are shown for parameters analysed by formal hypothesis testing. a Nominal P-value; formal hypothesis testing was stopped after FPG analysis. b For variables for which change from baseline is calculated as a ratio and reported as geometric LSM (SE), baseline and endpoint values are reported as geometric mean (SE). SE is reported as the measure of variance for the geometric mean for the following reasons: geometric mean is the exponential of the mean obtained on the logarithm scale. The geometric SE is a symmetric parameter that shows the precision of the geometric mean, whereas geometric SD is not a symmetric parameter and is difficult to present in a tabulation format for interpretation.
| Cardiovascular risk markers
Body weight decreased over the 28-week treatment period with exenatide QWS-AI and sitagliptin, with no difference observed between groups (nominal P = .8625) (Table 2; Figure 2E ). Most other cardiovascular risk markers (eg, blood pressure, lipids) were unchanged from baseline and did not differ between groups, although heart rate increased by +2.7 beats/min from baseline among exenatide QWS-AI-treated patients ( Table 2 ; Table S1 ).
| Patient-reported outcomes
Results of patient-reported outcome surveys (Diabetes Medication
Satisfaction Tool, Impact of Weight on Quality of Life-Lite), which demonstrated improvements from baseline, are provided in Table S1 .
| Exenatide pharmacokinetics
For the 134 patients in the pharmacokinetic-evaluable population, plasma exenatide concentrations were similar at weeks 8, 16 and 
| Safety and tolerability
AEs were reported by 55.8%, 32.8% and 47.5% of exenatide QWS-AI, sitagliptin and placebo recipients, respectively, during the 28-week treatment period (Table 3) . Table 3 ).
Of 24 suspected events submitted to the CEC committee for adjudication, 4 were confirmed (brain stem infarction, breast cancer and benign fibroadenoma of the breast with exenatide QWS-AI, and AMI with placebo). No thyroid neoplasm, pancreatic cancer, renal failure or pancreatitis events were reported in any group (Table 3) .
No major hypoglycaemia episodes were reported. One sitagliptin recipient had a minor hypoglycaemic event, and symptoms of hypoglycaemia occurred in 4 exenatide QWS-AI recipients, in 7 sitagliptin recipients and in 2 placebo recipients ( 
| DISCUSSION
Administration frequency and ease of use may affect patients' ability to initiate and continue injectable therapies for long-term use. Exenatide QWS-AI is a new formulation that does not require reconstitution and can be administered via autoinjector pen, simplifying use.
This study directly compared the efficacy and safety of exenatide QWS-AI with the oral DPP-4i sitagliptin or placebo over 28 weeks among patients with T2D who had insufficient glycaemic control on metformin monotherapy and found that exenatide QWS-AI was superior to sitagliptin and placebo for the primary endpoint of change from baseline in HbA1c at 28 weeks. Furthermore, more exenatide QWS-AI-treated patients achieved target HbA1c <7.0% at 28 weeks than did sitagliptin-or placebo-treated patients.
The effect of exenatide QWS-AI on HbA1c in this study is comparable to that observed with GLP-1RAs vs DPP-4is in previous studies. Of 8 randomized, head-to-head studies comparing the GLP-1RAs exenatide, liraglutide, albiglutide or dulaglutide with the DPP-4i sitagliptin as add-on therapy 9, [11] [12] [13] [15] [16] [17] [18] or monotherapy, 10 6 studies demonstrated significantly greater HbA1c reductions over 26 to 104 weeks with GLP-1RAs vs sitagliptin 9,10,12,15,16,18 ; 1 24-week study found no significantly different reductions with liraglutide 0.9 mg/d vs sitagliptin, 17 and 1 26-week study found that sitagliptin was noninferior to liraglutide 1.2 mg/d. 13 Additionally, a 24-week study found significantly greater HbA1c reductions with liraglutide vs saxagliptin or vildagliptin. 14 In 7 of the 9 earlier studies, proportions of patients achieving HbA1c levels <7.0% were greater with GLP-1RAs than DPP-4is. 9, 10, 12, 13, 15, 16, 18 FPG reductions in this trial were less robust than those with exenatide in previous trials. Based on nominal P-values, exenatide QWS-AI reduced FPG more than sitagliptin from weeks 8 to 24, but the difference was nonsignificant at week 28. Among previous studies comparing GLP-1RAs to DPP-4is, 8 (including 2 exenatide vs sitagliptin studies) found significantly greater FPG reductions with GLP-1RAs, 9, 10, 12, [14] [15] [16] [17] [18] and 1 study of liraglutide 1.2 mg/d found comparable reductions. 13 The statistical power in this study was probably insufficient to detect a difference because of the high FPG variability.
In this study, body weight loss was greater with exenatide QWS-AI than with placebo but similar to body weight loss with sitagliptin.
Among earlier studies comparing GLP-1RAs with DPP-4is, 9, 10, [12] [13] [14] [15] [16] [17] [18] weight loss of 1.1 kg with exenatide QWS-AI in this study. 9, 10, 19, 20 Similarly, the absence of blood pressure reduction observed in this study, which differs from previous studies of exenatide QW, 9, 10, 19 may be associated with the lesser body weight loss observed with exenatide QWS-AI. A post-hoc analysis showed that patients in the lower quartiles of weight loss after treatment with exenatide QW had less reduction in systolic blood pressure. 21 Although comparisons between studies and formulations are difficult, lower plasma exenatide concentrations in this study may have contributed to lower than expected weight reduction and, possibly, to less systolic blood pressure reduction. 22 The exenatide concentration required to improve glycaemic control is significantly less than that provided by either exenatide QW (aqueous) 21 or exenatide QWS-AI, but the concentration needed for body weight loss is close to the mean exenatide concentration measured in this study. 23 Further evaluation of the effects of exenatide QWS-AI on body weight is warranted.
This study also found that pancreatic β-cell function increased more with exenatide QWS-AI than with sitagliptin, consistent with previous findings for GLP-1RAs vs DPP-4is. 10, 15, 16 A significant difference in insulin sensitivity between exenatide QWS-AI and sitagliptin was also observed, which is different from earlier studies that have reported no between-group differences for changes in insulin sensitivity. 10, [15] [16] [17] This effect may be driven by higher fasting insulin concentrations with exenatide QWS-AI than with sitagliptin. There were no differences between groups in mean daily glucose reductions observed in this study, whereas earlier studies consistently found greater improvements with GLP-1RAs vs DPP-4is. 9, 10, 14, 18 Finally, a greater increase in fasting insulin was observed in this study with exenatide vs sitagliptin, consistent with the DURATION-2 study; 9 other studies did not find between-group differences in this measure. [15] [16] [17] Overall, based on all comparative data, one may conclude that the profile of exenatide QWS-AI is similar to that of exenatide QW and other GLP-1RAs, although some variability exists in results among different studies.
Interpretation of the data in this study is limited by several factors. One limitation of the study design was the lack of blinding for patients receiving exenatide QWS-AI, which may introduce observer or reporter bias, particularly for patient-reported outcomes. Although this approach avoided unnecessary injections for patients, it is possible that patient responses were biased by the knowledge that injected treatment was active. However, clinical trials with injectable
therapies are often open label, to minimize the burden to patients in the trial. This approach is accepted by regulatory authorities for indication-seeking trials. The oral placebo group in this study provided a reasonable assessment of the study bias in itself. Other limitations of this study design include the imbalanced randomization ratio, which reduced the power of the study to detect differences between groups, because of the relatively small placebo group that was chosen to minimize the number of untreated patients. The meal test cohort was also small, and the study duration was less than 1 year.
The incidence of AEs in this study was generally similar to that observed in other studies comparing GLP-1RAs with the DPP-4is sitagliptin, 12, 13, 15, 18, 24, 25 saxagliptin or vildagliptin. 14 These events were well tolerated, with no treatment withdrawals.
There were 5 SAEs with exenatide QWS-AI and none with sitagliptin.
There were no cases of major hypoglycaemia during the study, and 1 instance of minor hypoglycaemia with sitagliptin.
Consistent with observations concerning exenatide QW (aqueous), 26 the majority of exenatide QWS-AI recipients developed anti-exenatide antibodies. Patients with antibodies more often experienced injection-site reactions, and those with high-positive antibody levels had numerically lower HbA1c reduction (−0.6% vs −1.1% for those who were antibody-negative). Antibody effects on HbA1c reduction are not seen consistently in exenatide studies. 27 In this study, the exenatide QWS-AI formulation was compared with a DPP-4i. Another study (DURATION-NEO-1) compared the efficacy and safety of exenatide QWS-AI with exenatide BID in patients with T2D who were inadequately controlled with diet and exercise alone or with glucose-lowering therapies. 28 QWS-AI appeared larger than those in the current study. There are no obvious explanations for differences in efficacy data between the 2 studies, which may result from random variability in findings across studies or from undefined differences between patient populations.
In conclusion, this study demonstrated that exenatide QWS-AI was superior to sitagliptin in reducing HbA1c and in achieving the HbA1c target of <7.0%. While statistical superiority vs sitagliptin was not demonstrated for some secondary endpoints, both treatments reduced FPG and body weight, with few SAEs in any group. Gastrointestinal events were more common with exenatide QWS-AI than with sitagliptin. Overall evidence suggests that an injectable therapy administered QW may be an alternative to daily oral therapy for patients with T2D.
